

●▶ **Celltrion**

(FDA, Phase 3)

Celltrion's YUFLYMA receives FDA interchangeable designation, supported by positive Phase 3 study data for moderate-to-severe plaque psoriasis

●▶ **Wayfinder Biosciences + Daiichi Sankyo**

(Collaboration)

"Wayfinder and Daiichi Sankyo have announced an R&D collaboration in neurodegeneration

●▶ **Eli Lilly**

(Clinical data, Phase 3)

Lilly's oral GLP-1, orforglipron, has met its primary endpoints in a Phase 3 trial, demonstrating significant efficacy and safety comparable to injectable GLP-1 therapies

●▶ **Sanofi + Earendil Labs**

(Agreement)

"Earendil Labs and Sanofi have entered into a license agreement for two potential first-in-class bispecific antibodies, HXN-1002 and HXN-1003, targeting autoimmune and inflammatory bowel diseases

